Knight Therapeutics Inc.
KHTRF
$5.32
$0.030.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.11% | 15.67% | 10.60% | 8.76% | 11.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.11% | 15.67% | 10.60% | 8.76% | 11.36% |
| Cost of Revenue | 24.71% | 28.50% | 22.16% | 11.19% | 10.32% |
| Gross Profit | 12.79% | 1.91% | -1.74% | 5.95% | 12.55% |
| SG&A Expenses | 22.66% | 19.40% | 16.39% | 13.75% | 16.84% |
| Depreciation & Amortization | 9.61% | 0.62% | -9.53% | -6.82% | -2.98% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.17% | 22.45% | 15.85% | 10.03% | 11.26% |
| Operating Income | -128.89% | -208.10% | -206.56% | -113.47% | 16.46% |
| Income Before Tax | -478.82% | 68.90% | 68.39% | 135.62% | 108.04% |
| Income Tax Expenses | 45.36% | -391.07% | -204.87% | 69.58% | 56.84% |
| Earnings from Continuing Operations | -236.11% | 88.13% | 100.84% | 161.52% | 123.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -236.11% | 88.13% | 100.84% | 161.52% | 123.95% |
| EBIT | -128.89% | -208.10% | -206.56% | -113.47% | 16.46% |
| EBITDA | -13.36% | -32.83% | -33.71% | -8.28% | 3.79% |
| EPS Basic | -235.14% | 87.40% | 100.39% | 162.16% | 124.96% |
| Normalized Basic EPS | -248.36% | -257.97% | -267.27% | -103.21% | -32.38% |
| EPS Diluted | -285.25% | 83.24% | 95.02% | 155.29% | 119.40% |
| Normalized Diluted EPS | -248.36% | -257.97% | -267.27% | -103.21% | -32.38% |
| Average Basic Shares Outstanding | -1.46% | -1.94% | -2.80% | -4.05% | -6.00% |
| Average Diluted Shares Outstanding | -1.32% | -1.73% | -2.65% | -3.95% | -6.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |